Download MendeleyFunctional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation.
Sun, Y., Bandi, M., Lofton, T., Smith, M., Bristow, C.A., Carugo, A., Rogers, N., Leonard, P., Chang, Q., Mullinax, R., Han, J., Shi, X., Seth, S., Meyers, B.A., Miller, M., Miao, L., Ma, X., Feng, N., Giuliani, V., Geck Do, M., Czako, B., Palmer, W.S., Mseeh, F., Asara, J.M., Jiang, Y., Morlacchi, P., Zhao, S., Peoples, M., Tieu, T.N., Warmoes, M.O., Lorenzi, P.L., Muller, F.L., DePinho, R.A., Draetta, G.F., Toniatti, C., Jones, P., Heffernan, T.P., Marszalek, J.R.(2019) Cell Rep 26: 469-482.e5
- PubMed: 30625329
- DOI: https://doi.org/10.1016/j.celrep.2018.12.043
- Primary Citation of Related Structures:
5UQ9 - PubMed Abstract:
The plasticity of a preexisting regulatory circuit compromises the effectiveness of targeted therapies, and leveraging genetic vulnerabilities in cancer cells may overcome such adaptations. Hereditary leiomyomatosis renal cell carcinoma (HLRCC) is characterized by oxidative phosphorylation (OXPHOS) deficiency caused by fumarate hydratase (FH) nullizyogosity. To identify metabolic genes that are synthetically lethal with OXPHOS deficiency, we conducted a genetic loss-of-function screen and found that phosphogluconate dehydrogenase (PGD) inhibition robustly blocks the proliferation of FH mutant cancer cells both in vitro and in vivo. Mechanistically, PGD inhibition blocks glycolysis, suppresses reductive carboxylation of glutamine, and increases the NADP + /NADPH ratio to disrupt redox homeostasis. Furthermore, in the OXPHOS-proficient context, blocking OXPHOS using the small-molecule inhibitor IACS-010759 enhances sensitivity to PGD inhibition in vitro and in vivo. Together, our study reveals a dependency on PGD in OXPHOS-deficient tumors that might inform therapeutic intervention in specific patient populations.
Organizational Affiliation:
Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Center for Co-Clinical Trials, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: ysun8@mdanderson.org.
